Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Equivalents (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Cash & Equivalents data on record, last reported at $222.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents changed N/A year-over-year to $222.0 million; the TTM value through Dec 2025 reached $222.0 million, changed N/A, while the annual FY2025 figure was $222.0 million, N/A changed from the prior year.
  • Cash & Equivalents reached $222.0 million in Q4 2025 per RCUS's latest filing, down from $238.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $549.0 million in Q1 2022 and bottomed at $127.0 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $239.6 million, with a median of $220.0 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 479.66% in 2021, then tumbled 56.65% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $148.0 million in 2021, then skyrocketed by 39.19% to $206.0 million in 2022, then plummeted by 38.35% to $127.0 million in 2023, then soared by 58.27% to $201.0 million in 2024, then rose by 10.45% to $222.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $222.0 million in Q4 2025, $238.0 million in Q3 2025, and $248.0 million in Q2 2025.